Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms [In-111]DTPA-dinutuximab-IRDye800CW, DTPA[Indium-111]-dinutuximab-IRDye800CW |
Target |
Action inhibitors |
Mechanism GD2 inhibitors(Disialoganglioside GD2 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
RegulationOrphan Drug (United States) |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neuroblastoma | Discovery | United States | 31 Jul 2023 |






